Search

Your search keyword '"Connolly, Stuart"' showing total 2,581 results

Search Constraints

Start Over You searched for: Author "Connolly, Stuart" Remove constraint Author: "Connolly, Stuart"
2,581 results on '"Connolly, Stuart"'

Search Results

2. The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective

4. Semi-Markov Offline Reinforcement Learning for Healthcare

8. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA

11. Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes

14. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation

16. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials

18. Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials.

22. Benzodiazepine-Free Cardiac Anesthesia for Reduction of Postoperative Delirium (B-Free): A Protocol for a Multi-centre Randomized Cluster Crossover Trial

23. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial

25. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

26. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

27. Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.

29. Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

30. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

32. Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry

34. Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction

44. Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy

45. Restricted versus liberal intraoperative benzodiazepine use in cardiac anaesthesia for reducing delirium (B-Free Pilot): a pilot, multicentre, randomised, cluster crossover trial

46. Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials

47. ANDEXANET ALFA VS NON-SPECIFIC TREATMENTS FOR INTRACEREBRAL HEMORRHAGE IN PATIENTS TAKING FACTOR XA INHIBITORS – INDIVIDUAL PATIENT DATA ANALYSIS OF ANNEXA-4 AND TICH-NOAC

48. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors

49. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor–Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care

50. Risk Factors for Infections Involving Cardiac Implanted Electronic Devices

Catalog

Books, media, physical & digital resources